Samsung Biologics, a contract development and manufacturing organization (CDMO), has acquired a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in the United States. The Rockville site comprises two cGMP manufacturing plants with a combined 60,000-liter drug substance capacity, supporting both clinical and commercial biologics production across multiple manufacturing scales. With this addition, Samsung Biologics’ total global man...